Pharmaceutical

According to the families of the affected children, initially, the children suffered from colds, coughs, and fevers. After that, their kidneys become affected, and their condition worsens.

Trump's 100% tariff on branded drugs: Exporters assessing impact on complex generics

Pharmexcil, the sector's leading export body, said it is prudent to stay prepared for any future policy shift and build risk-mitigation strategies.

FTAs are welcome but don’t let them undermine pharma industry and drug access

In last two decades, the country’s IP model continues to serve as a global benchmark for balancing innovation with public health. India’s philosophy remains rooted in a simple principle: innovation and access are not competing goals; they are complementary imperatives. Good health policy isn’t about choosing between science and society; it’s about designing systems where both can thrive, and India’s IP framework proves it’s possible

Pharma stocks rise up to 4% after better-than-expected Trump order on lower drug prices

On May 13, Nifty Pharma index was trading 1.3% higher while the benchmark indices were trading nearly 1% lower

Sun Pharma’s Q2 net profit jumps 28% on-year to Rs 3,040 crore, beats expectations

Sun Pharmaceutical Q2 FY25 Results: Analysts expected India's largest drugmaker's net profit to jump, led by favourable seasonality and strong specialty sales.

ICMR, Panacea Biotec initiate 1st ever phase-three clinical trial for dengue vaccine in India

The phase three clinical trial will be conducted across 19 sites in 18 states and union territories, involving more than 10,335 healthy adult participants.

Sun Pharma Q1 Results: Net profit jumps 40% on-year to Rs 2,836 crore, beats estimates

Sun Pharmaceutical Q1 FY25 Results: India formulation sales grew by 16.4 percent to Rs 4,144 crore, accounting for about 33.1 percent of total consolidated sales.

Cipla Q1 Results: Net profit rises to Rs 1,178 crore, beats estimate

Cipla Q1 FY25 Results Update: A Moneycontrol poll of 9 brokerage estimates had pegged Cipla's fiscal first quarter net profit at Rs 1,116 crore and revenue at Rs 6,788 crore.

Steady US sales to bring a healthy quarter for pharma sector

After witnessing consistent double-digit growth in branded formulations business in recent years, growth in the domestic formulation segment has moderated to high single digits

Indian pharmaceutical market registers 9.5% growth in March

While most of the corporates have shown double digit value growth, unit growth remains a challenge for the Indian pharma market, according to analysts

Essential medicines to be slightly costlier from April 1

There are around 800 drugs on the National List of Essential Medicines maintained by the Department of Pharmaceuticals. The pricing is arrived at by the National Pharmaceutical Pricing Authority on the basis of the WPI of the previous calendar year.

Why government is cracking down on junkets, gifts for doctors by pharma firms

The new rules state that pharma companies or their representatives should not offer hotel stays, expensive cuisine, etc, to healthcare professionals or their family members

Will a new pharmaceutical marketing code succeed where earlier attempts failed?

The code’s voluntary nature and past experience does not inspire confidence in its implementation. Apart from companies, there is a dire need to regulate the other side of the table as well

Sun Pharma to acquire 16.33% stake of Surgimatix for $3.05 million

Surgimatix is engaged in developing a proprietary soft tissue fixation device for laparoscopic hernia repair and other minimally invasive surgeries

JB Pharma Q2 results: Net Profit up 35% to Rs 150.5 crore

The pharma company had reported a net profit of Rs 111.1 crore in the year-ago period.

Low expectations ahead of September quarter earnings 

More than the historical numbers, the market would be keen to hear from the management regarding their outlook in the current uncertain environment. 

Aurobindo Pharma’s Telangana plant classified as VAI by US FDA

The US FDA conducted an inspection at Aurobindo Pharma Limited, Bachupally Village, Telangana from July 14-21

Lupin Q1 results: Net profit at Rs 453.33 crore from year-ago loss, tops Street estimates

The Street had pegged Lupin’s net profit at Rs 276.2 crore for the April- June quarter

Zydus Lifescience Q1 PAT seen up 58.6% YoY to Rs 839.1 cr: Nirmal Bang

Net Sales are expected to increase by 24 percent Y-o-Y (up 0.8 percent Q-o-Q) to Rs 5,050.3 crore, according to Nirmal Bang.

Torrent Pharma Q1 PAT may dip 9.7% YoY to Rs 319.7 cr: Nirmal Bang

Net Sales are expected to increase by 11 percent Y-o-Y (up 4.6 percent Q-o-Q) to Rs 2,604.6 crore, according to Nirmal Bang.

Sun Pharma Q1 PAT seen up 8.6% YoY to Rs 2,238.8 cr: Nirmal Bang

Net Sales are expected to increase by 9.5 percent Y-o-Y (up 7.8 percent Q-o-Q) to Rs 11,784.7 crore, according to Nirmal Bang.

Natco Q1 PAT seen up 36.2% YoY to Rs 436.5 cr: Nirmal Bang

Net Sales are expected to increase by 35.1 percent Y-o-Y (up 33.1 percent Q-o-Q) to Rs 1,195.4 crore, according to Nirmal Bang.

Indoco Remedies Q1 PAT may dip 0.1% YoY to Rs 38.5 cr: Nirmal Bang

Net Sales are expected to increase by 6.8 percent Y-o-Y (up 1.8 percent Q-o-Q) to Rs 435.9 crore, according to Nirmal Bang.

Gland Pharma Q1 PAT may dip 14.6% YoY to Rs 195.8 cr: Nirmal Bang

Net Sales are expected to increase by 40.3 percent Y-o-Y (up 53.1 percent Q-o-Q) to Rs 1,210.9 crore, according to Nirmal Bang.

Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang

Net Sales are expected to increase by 22.3 percent Y-o-Y (down 3.1 percent Q-o-Q) to Rs 6,099.1 crore, according to Nirmal Bang.